开能健康(300272) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥496,533,217.75, representing a 21.08% increase compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥58,432,575.30, a significant increase of 106.86% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥53,554,323.42, up 148.16% from the previous year[5] - Basic earnings per share for Q3 2022 were ¥0.11, reflecting a 120.00% increase compared to the same period last year[5] - Total operating revenue for the current period reached ¥1,243,354,932.90, an increase of 12.5% compared to ¥1,105,083,748.49 in the previous period[27] - Net profit for the current period was ¥101,936,358.39, representing a 1.9% increase from ¥99,969,154.95 in the same period last year[28] - Basic earnings per share increased to ¥0.16 from ¥0.15, reflecting a growth of 6.7%[29] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥2,286,993,894.78, an increase of 7.23% from the end of the previous year[5] - Shareholders' equity attributable to the parent company was ¥1,241,036,284.81, up 3.21% from the end of the previous year[5] - The company's total liabilities reached CNY 1,013,222,649.49, up from CNY 880,632,931.34, marking an increase of about 15%[26] - The total current liabilities rose to CNY 875,629,787.55, compared to CNY 753,985,852.40 at the beginning of the year, indicating an increase of about 16%[25] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥59,463,340.16, showing a decrease of 52.26% compared to the same period last year[5] - Cash flow from financing activities increased significantly by 124.36% to ¥10,171,466.80, driven by a net inflow of borrowings compared to the previous year[11] - The net cash flow from investment activities was -43,138,518.25, compared to -92,964,254.00 in the previous year, indicating an improvement[31] - The cash and cash equivalents at the end of the period amounted to 299,528,280.69, compared to 152,213,147.56 at the end of the previous year[31] Expenses and Costs - Total operating costs amounted to ¥1,126,946,208.17, up 13.1% from ¥996,462,312.81 in the prior period[27] - R&D expenses rose by 28.32% to CNY 45.23 million as the company enhanced its product development efforts[10] - The company reported a tax expense of ¥15,655,728.14, slightly higher than ¥15,240,112.02 in the previous period[28] - The company reported a 245.73% increase in taxes and surcharges, mainly due to increased urban construction tax and property tax provisions[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,447, with the largest shareholder, Qu Jianguo, holding 33.72% of the shares[12] - Qu Jianguo, the controlling shareholder, has committed to relinquishing voting rights for 54,331,600 shares, representing 9.4134% of the total share capital[15] - The controlling shareholder, Mr. Qu Jianguo, donated 26 million shares, reducing his ownership from 38.90% to 34.32%, while the recipient foundation's ownership increased from 1.22% to 5.80%[19] Investments and Acquisitions - The company invested CNY 10.1 million in Yuan Energy Bio, increasing its shareholding from 6.57% to 11.82% after the capital increase[21] - The company has filed a civil lawsuit seeking CNY 20 million in damages related to an investment in the Houyu Fund, which remains unrecovered[22] - The company plans to further assess impairment losses related to its investment in the Houyu Fund based on ongoing communications with the fund manager[21] Other Comprehensive Income - Other comprehensive income increased by 585.63% primarily due to exchange rate changes and foreign currency translation[9] - Other comprehensive income after tax amounted to ¥13,358,792.41, compared to a loss of ¥739,499.56 in the previous period[28]